HDBuzz
- Company typePrivate
- Founded2011
- HeadquartersPerú, Colombia
- Headcount1–10
- GTM typeB2C
- OfferingDigital Commerce or Content
HDBuzz firmographics
Firmographics- Name
- HDBuzz
- Legal name
- HDBuzz
- Website
- https://en.hdbuzz.net
- Company type
- Private
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
HDBuzz industry classification
Industry- Product category
- Health & Medical Research News
- NAICS
- Information (51)
- SIC
- Services-Misc Health & Allied Services, Nec (8090)
- akta.pro primary industry
- DTx/SaMD Evidence, Outcomes & Real-World Data (RWE) Platforms (HLACANAM)
Keywords
Where HDBuzz is headquartered
LocationHeadquarters
- HQ city
- Perú
- HQ country
- Colombia
- HQ region
- Latin America
Markets served
HDBuzz business model
Business model- GTM type
- B2C
- Offering type
- Digital Commerce or Content
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D
Revenue model
- Donations and Grants: HDBuzz is funded through donations and grants. The site operates as a non-profit scientific communication service. The Funding page explains their financial model ensures neutrality and reliability.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Freemium | Others | Free access to all HDBuzz content |
Go-to-market motion1 record
Distribution channels5 records
Marketing channels7 records
HDBuzz product offering
Product offeringCore offering
HDBuzz is a non-profit online publishing platform that produces and distributes Huntington's disease research news in plain language, written by scientists for the global HD community. The platform publishes articles, conference coverage, and clinical trial updates, and supports a Trial Tracker database covering active HD drug development programs. All content is freely accessible under Creative Commons licensing and distributed in 12+ languages.
Product overview
HDBuzz is a unified digital research news platform providing Huntington's disease (HD) information in plain language, written by scientists for the global HD community. The core offering consists of the HDBuzz Research News Platform delivering articles, conference coverage, and clinical trial updates, supported by the HDBuzz Trial Tracker database. Additional services include a Glossary resource, multilingual content in 12+ languages, the HDBuzz Prize for Young Science Writers competition, and annual reports. The platform disseminates content through its website, social media channels (Instagram, Bluesky, Facebook, YouTube), RSS Feed, and email subscriptions.
Differentiator
Problem solved
Functional benefit
Products and services
- HDBuzz Research News Platform A digital news platform providing Huntington's disease research news in plain language, written by scientists for the global HD community. Features articles, clinical trial updates, and conference coverage.
- HDBuzz Trial Tracker A curated database tracking Huntington's disease clinical trials, including drug development programs from companies like uniQure, Roche, Skyhawk Therapeutics, Novartis/PTC Therapeutics, Wave Life Sciences, Vico Therapeutics, Alnylam Pharmaceuticals, and SOM Biotech, with trial status and timeline information.
- HDBuzz Glossary An educational reference resource explaining Huntington's disease terminology and scientific concepts in accessible language.
- HDBuzz Multilingual Content Research news articles translated into 12+ languages including Simplified Chinese, Dutch, French, German, Italian, Korean, Persian, Polish, Portuguese, Russian, and Spanish.
- HDBuzz Prize for Young Science Writers An annual competition for early-career researchers to write about Huntington's disease in accessible language, with monetary prizes and global publication of winning entries, supported by the Hereditary Disease Foundation.
Quantifiable outcome
- Reached 329,000 people in 2025 with independent HD research news
Companies that use HDBuzz
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
HDBuzz technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
HDBuzz partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and minor.
- Huntington Study GroupcoreHuntington Study Group is an organization with many years of experience running HD clinical trials. They partnered with Spark/Roche to carry out the SPK-10001/RG6662 gene therapy trial. HDBuzz covers their activities and trial recruitment information.
- CHDI FoundationcoreCHDI Foundation is described as the biggest funder and driver of HD research worldwide. HDBuzz provides coverage of CHDI's annual Huntington's Disease Therapeutics Conference, with HDBuzz staff attending and providing live updates. This is a key partnership for disseminating HD research findings to the broader community.
- Hereditary Disease FoundationminorThe Hereditary Disease Foundation provides financial support for the annual HDBuzz Prize for Young Science Writers competition, encouraging early-career researchers to communicate HD science in accessible language.
Scale indicators3 records
Recent moves6 records
Expansion highlights4 records
HDBuzz competitors and assessment
Company assessmentBroad incumbents
- NORD (National Organization for Rare Disorders): NORD is a broad umbrella advocacy and information organization for rare diseases, including Huntington's disease. It serves a similar patient-information function but across hundreds of conditions rather than specializing in HD.
- Orphanet: Orphanet is a pan-European reference portal for rare diseases and orphan drugs, providing structured disease and trial information including for Huntington's disease. Its encyclopedic, multi-disease scope contrasts with HDBuzz's disease-specialized editorial approach.
- CHDI Foundation: CHDI is described as the largest funder of HD research globally and a strategic partner of HDBuzz. Although CHDI funds drug discovery rather than operating a public news platform, it is the dominant incumbent in the HD information ecosystem and shapes editorial context.
- Huntington Study Group: HSG is a longstanding clinical research cooperative running HD trials (e.g., the Spark/Roche SPK-10001/RG6662 gene therapy program). Its trial-information dissemination role overlaps with HDBuzz's Trial Tracker, though HSG focuses on investigator-facing rather than patient-facing communication.
Direct peers
- Friedreich's Ataxia Research Alliance (FARA): FARA is a rare-disease organization that combines patient community support with research dissemination for Friedreich's ataxia, a hereditary neurological disease. Its blend of advocacy, scientific communication, and patient engagement parallels HDBuzz's model in a closely comparable rare-disease context.
- The Michael J. Fox Foundation for Parkinson's Research: MJFF combines Parkinson's research funding, patient education, and plain-language dissemination of trial and therapeutic news. Its hybrid research/communication model for a specific neurodegenerative disease community closely mirrors HDBuzz's positioning.
- BioNews: BioNews is the parent company behind dozens of 'Disease News Today' sites (e.g., SMA News Today, Parkinson's News Today, ALS News Today) that deliver plain-language research news for rare and chronic disease communities. Its vertical-specific, patient-focused model is structurally identical to HDBuzz's approach.
- Alzforum: Alzforum is a scientist-written research news platform covering Alzheimer's disease and related neurodegenerative disorders. It is the closest analog to HDBuzz: a free, independent, expert-authored news service serving patients, families, and clinicians in a specific neurodegenerative disease community.
- Cure SMA: Cure SMA supports patients with spinal muscular atrophy and funds/disseminates research updates. Like HDBuzz, it operates as a patient-facing hub for plain-language scientific news in a rare genetic neurological disease with active therapeutic development.
- ALS Therapy Development Institute: ALS TDI conducts and disseminates ALS research while maintaining patient and clinician-facing communication. The hybrid research-plus-translation model for a specific neurodegenerative disease community is structurally analogous to HDBuzz.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
HDBuzz social profiles
Digital presenceHDBuzz financial estimates
Financial estimateRevenue estimate
Valuation estimate
HDBuzz leadership team
Management profileNumber of profiles
Profiles5 records
HDBuzz funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
HDBuzz M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about HDBuzz
What does HDBuzz do?
HDBuzz is a non-profit online publishing platform that produces and distributes Huntington's disease research news in plain language, written by scientists for the global HD community. The platform publishes articles, conference coverage, and clinical trial updates, and supports a Trial Tracker database covering active HD drug development programs. All content is freely accessible under Creative Commons licensing and distributed in 12+ languages.
Is HDBuzz a public or private company?
HDBuzz is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was HDBuzz founded?
HDBuzz was founded in 2011. It employs 1 to 10 people.
Where is HDBuzz based?
HDBuzz is headquartered in Perú, Colombia, in the Latin America region.
How does HDBuzz make money?
One revenue line is on record: donations and Grants.
Who are HDBuzz's main competitors?
Broad incumbents on record are NORD (National Organization for Rare Disorders), Orphanet, CHDI Foundation and Huntington Study Group. Direct peers are Friedreich's Ataxia Research Alliance (FARA), The Michael J. Fox Foundation for Parkinson's Research, BioNews, Alzforum, Cure SMA and ALS Therapy Development Institute.
Does HDBuzz have an API?
No public API is recorded for HDBuzz.
What industry is HDBuzz in?
HDBuzz's product category is Health & Medical Research News. Its primary akta.pro industry code is HLACANAM, DTx/SaMD Evidence, Outcomes & Real-World Data (RWE) Platforms. Its NAICS code is 51 and its SIC code is 8090.